CYCLO THERAPEUTICS INC (CYTH) Stock News

Which stocks are experiencing notable movement on Monday?

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Monday's pre-market session: top gainers and losers

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, FLIC, ARCH, CYTH on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARCH, CYTH on Behalf of Shareholders

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, CYTH, ARCH on Behalf of Shareholders

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders

Gold Down Over 1%; US Initial Jobless Claims Increase

CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH Stock Earnings: Cyclo Therapeutics Misses EPS, Misses Revenue for Q2 2024

CYTH stock results show that Cyclo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update